Product Introduction:
Triglynase 2 Tablet SR is a combination antidiabetic medicine used to manage type 2 diabetes mellitus in adults. It helps control blood sugar levels by improving insulin utilization and sensitivity. This medicine is used along with a proper diet and regular exercise to achieve optimal glucose control.
It should be taken with food to prevent stomach upset. Take it regularly at the same time each day, as advised by your doctor.
Composition:
Glimepiride + Metformin + Pioglitazone
Uses:
Treatment of Type 2 Diabetes Mellitus
Benefits:
Helps lower and maintain blood glucose levels.
Improves insulin sensitivity and glucose utilization.
Reduces the risk of diabetes-related complications such as nerve, kidney, and eye damage.
Promotes better metabolic control when single or dual therapy is insufficient.
Directions for Use:
Take as advised by your doctor. Swallow the tablet whole with water — do not crush or chew. Always take it with meals to minimize gastrointestinal side effects.
How It Works:
Triglynase 2 Tablet SR combines three antidiabetic agents:
Glimepiride: Stimulates the pancreas to release more insulin.
Metformin: Reduces glucose production in the liver and improves insulin sensitivity.
Pioglitazone: Increases insulin sensitivity in muscle and fat tissues.
Together, they help maintain stable blood sugar levels throughout the day.
Common Side Effects:
Hypoglycemia (low blood sugar)
Headache, dizziness
Nausea, vomiting, diarrhea
Weakness or fatigue
Stomach pain
Anemia
Respiratory tract infection
Safety Advice:
Alcohol: Unsafe; increases risk of low blood sugar.
Pregnancy: Consult your doctor; may be unsafe.
Breastfeeding: Not recommended.
Driving: Use caution if blood sugar levels fluctuate.
Kidney: Use with caution; avoid in severe impairment.
Liver: Use with caution; not recommended in severe liver disease.
1-Line Composition:
Glimepiride + Metformin + Pioglitazone Tablet SR
Short Use Description:
Used for the treatment of type 2 diabetes mellitus in adults.




Reviews
There are no reviews yet.